Our Privacy Policy

Arazy Group Consultants Inc. ("Arazy Group") respects your right to privacy and is providing this statement of privacy to inform you of our practices regarding personal content which you may provide to us through our websites or by any other means. This statement refers to the websites arazygroup.com and licensale.com, both owned by Arazy Group.

Arazy Group will not knowingly disclose personal and/or business identifiable information ("Identified Information") about you to any third-party unless it is required by law by any court order or search warrant, or unless you have given us your written permission to do so in advance.

However, Arazy Group may use any Identified Information that you have provided to us through our websites ONLY for the following purposes:

  • In order to provide you with our services.
  • In order to provide you with our newsletter and/or any other advertising materials which we may be interested to distribute from time to time to our potential clients and/or other business partners for marketing purposes.
  • Based on your request for information, in order to be able to communicate with you and/or contact you back in any way and for any sales promotion purposes or to use your professional services in the future. In such cases, we may keep a record of that correspondence and we may collect your name, email address, phone numbers, and other professional and personal information that you have provided to us.

Arazy Group may also collect, share and use anonymous, NON Identified Information regarding our web site users or any third parties in order to evaluate how the site is being used and for research purposes. This includes but not limited to IP address, browser type, referring pages, pages visited, and platform type. In some cases, we use third-party service providers to assist us with such analysis.

Arazy Group uses commercially reasonable safeguards to preserve the security of your personal and business information. Nevertheless, Arazy Group cannot ensure or warrant the security of any information provided to us through the websites. Any transmission of information is made at your own risk.

Arazy Group may store and process information in various locations around the globe. If you are a resident of a jurisdiction where transfer of your Identified Information to another jurisdiction requires your consent, then you hereby provide us with your express consent to such transfer of your data.

Once Arazy Group receives your information, we make commercially reasonable efforts to ensure the security of the websites. However, please note that this is not a guarantee that such information may not be accessed, disclosed, altered, or destroyed by breach of any of Arazy Group's safeguards.

If you no longer desire our services or would like to request that we delete your Identified Information, you may contact us at info@arazygroup.com.

latest news
  • Mar 21 2017
    MEET MDSAP TRANSITION DEADLINE TO CONTINUE TRADING ON CANADIAN MARKET

    In vitro diagnostic (IVD) and medical device manufacturers must transition to the Medical Device Single Audit Program (MDSAP) before January 1, 2019 in order to continue trading on the Canadian market. ...

    Read More
  • Mar 17 2017
    HAVE YOUR SAY ON CLASS II DEVICE PREMARKET NOTIFICATION EXEMPTION PROPOSAL

    The US Food and Drug Administration (FDA) is requesting public comments on a list of 1,003 class II devices that it is proposing to exempt or partially exempt from the premarket notification [510(k)] requirements. ...

    Read More
  • Mar 16 2017
    EMPOWERING REGULATORY AFFAIRS CONSULTANTS IN 100+ MARKETS

    Independent regulatory consultants are invited to register for exclusive offers that would enable them to instantly boost their MedTech product registration capabilities in 100+ markets worldwide and maximize their profit....

    Read More
  • Mar 13 2017
    REMINDER: SOUTH AFRICA’S MEDICINES CONTROL COUNCIL SETS LICENSING DEADLINES

    South Africa’s manufacturers, distributors and wholesalers of in vitro diagnostic (IVD) and medical devices must submit a license application to the Medical Control Council by the deadlines it announced in February 2017. ...

    Read More
  • Mar 7 2017
    REGULATORY UPDATE: LUMINEX

    BRAZIL: Luminex's MAGPIX® HW + SW + Reag & Calib was approved for sale with LICENSALE.COM®. ...

    Read More

VANCOUVER OFFICE

  • Phone +1 604.681.6888
  • Fax +1 604.681.6822
  • info@arazygroup.com
  •  
  • #350-1333 Johnston Street
  • Pier 32, Granville Island
  • Vancouver, British Columbia
  • Canada V6H 3R9

BACK TO TOP